Novartis AG NVSEF · Stock Open Novartis AG in new tab
Novartis AG Analysis (NVSEF)
Is Novartis AG a good investment? Novartis AG (NVSEF) is currently trading at 163.60 USD.
In terms of valuation, the stock trades at a P/E ratio of 24.68. This valuation is generally in line with the broader market.
Earnings Schedule: Novartis AG is expected to release its next earnings report on Oct. 27, 2026.
For income investors, Novartis AG pays a dividend yield of 2.89%. With a payout ratio of 70%, the dividend appears sustainable.
Investor FAQ
Does Novartis AG pay a dividend?
Yes, it pays an annual dividend of 4.73 USD (2.89% yield).
What asset class is Novartis AG?
Novartis AG is classified as a Stock. You can compare it against 8 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Oct. 27, 2026. The company currently has a trailing EPS of 6.63.
Company Profile
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Year | Total Dividends |
|---|---|
| ▸2027 |
4.98 USD
|
| March 5, 2027 (estimated) | 4.9796 |
| ▸2026 |
4.74 USD
|
| March 12, 2026 | 4.7401 |
| ▸2025 |
3.96 USD
|
| March 13, 2025 | 3.9648 |
| ▸2024 |
3.75 USD
|
| March 11, 2024 | 3.7543 |
| ▸2023 |
3.42 USD
|
| March 13, 2023 | 3.4158 |
| ▸2022 |
3.34 USD
|
| March 10, 2022 | 3.3372 |
| ▸2021 |
3.24 USD
|
| March 8, 2021 | 3.2426 |
| ▸2020 |
3.09 USD
|
| March 5, 2020 | 3.0874 |
| ▸2019 |
2.85 USD
|
| March 6, 2019 | 2.8505 |
| ▸2018 |
2.98 USD
|
| March 8, 2018 | 2.9811 |
| ▸2017 |
2.72 USD
|
| March 6, 2017 | 2.7199 |
| ▸2016 |
2.73 USD
|
| Feb. 29, 2016 | 2.7303 |
| ▸2015 |
2.71 USD
|
| March 5, 2015 | 2.7085 |
| ▸2014 |
2.75 USD
|
| March 4, 2014 | 2.7548 |
| ▸2013 |
2.47 USD
|
| March 1, 2013 | 2.4690 |
| ▸2012 |
2.50 USD
|
| March 1, 2012 | 2.5011 |
| ▸2011 |
2.37 USD
|
| March 1, 2011 | 2.3726 |
| ▸2010 |
1.95 USD
|
| March 5, 2010 | 1.9453 |
| ▸2009 |
1.71 USD
|
| Feb. 27, 2009 | 1.7102 |
| ▸2008 |
1.53 USD
|
| Feb. 29, 2008 | 1.5347 |
| ▸2007 |
1.10 USD
|
| March 9, 2007 | 1.0977 |
| ▸2006 |
0.88 USD
|
| March 3, 2006 | 0.8848 |
| ▸2005 |
1.05 USD
|
| March 4, 2005 | 1.0500 |
| ▸2004 |
1.00 USD
|
| Feb. 27, 2004 | 1.0000 |
| ▸2003 |
0.95 USD
|
| March 7, 2003 | 0.9500 |
| ▸2002 |
0.90 USD
|
| March 26, 2002 | 0.9000 |
| ▸2001 |
0.85 USD
|
| March 27, 2001 | 0.8500 |
| ▸2000 |
0.80 USD
|
| April 17, 2000 | 0.8000 |
| ▸1999 |
0.73 USD
|
| April 26, 1999 | 0.7250 |
| ▸1998 |
0.63 USD
|
| April 24, 1998 | 0.6250 |
| ▸1997 |
0.50 USD
|
| April 25, 1997 | 0.5000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Novartis AG | Mar 12, 2026 | Paid | 4.7401 USD |
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 4, 2023 | 1.05 |
Community Discussion